News

STAMPEDE has been shortlisted for the BMJ UK Research Paper of the Year award for the second year in a row; the first to be shortlisted twice for different papers. Now in their 10th year, The BMJ Awards are the UK's leading medical awards. They promote excellence in healthcare and recognise the inspirational work of healthcare teams across the country. This coveted award recognises original research that has the potential to contribute significantly to improving health and health care. MRC CTU at UCL has previously featured at the awards, with wins for ARROW and FEAST, and nominations for STAMPEDE and QUARTZ. A huge amount of work goes on within hospitals and the central coordinating centre across the length of a trial. The nomination is a timely reminder of the nature of these large collaborative projects, which typically run over many years. The shortlisted paper is titled 'Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.' "Abiraterone not only prolon ...

Docetaxel or abiraterone, in addition to standard care, are very effective treatments for men with prostate cancer due to start long-term hormone therapy. Findings from the STAMPEDE trial and STOPCAP network meta-analysis, helping clinicians to choose between them, were published recently in Annals of Oncology. The STAMPEDE trial, directly compared men recruited to the trial between November 2011 and March 2013. Patients were randomised to receive either docetaxel plus standard hormone therapy, or abiraterone plus standard hormone therapy. This is the first direct randomised data comparing the two treatments. The STOPCAP network meta-analysis represents the most comprehensive and reliable assessment of the effects of current treatment options for men whose prostate cancer has spread, and who are starting long-term hormone therapy for the first time.  Results based on all current trial data show that abiraterone plus standard hormone therapy is most likely to be the best treatment; do ...

As the STAMPEDE trial recruits its 10,000th participant, we would like to mark this milestone and take the opportunity to thank everyone involved, particularly participants and their families, all the hundreds of hospital staff involved and the staff at the MRC CTU at UCL. It would not be possible to help improve care for men with advanced prostate cancer without the dedication and continued involvement of all of these people. Impact on treatments for patients with prostate cancer STAMPEDE is the largest ever prostate cancer treatment trial. The study has already demonstrated improved survival with the addition of either docetaxel or abiraterone to standard-of-care treatment for men starting long-term hormone therapy. The clinical results from STAMPEDE on docetaxel were published in early 2016 and have changed the treatment for men with prostate cancer worldwide. Docetaxel is now available on the NHS to men with cancer that has spread to distant parts of their body. However, it is ...

Adding the drug docetaxel to standard hormone therapy is cost-effective when used to treat men with locally-advanced or advanced prostate cancer. This is according to results from the STAMPEDE trial which were presented yesterday at the Genitourinary Cancers Symposium in San Francisco. Previous results from the STAMPEDE trial have shown that adding the chemotherapy drug docetaxel to standard hormone therapy improves how long men with prostate cancer live by about 10 months, compared to hormone therapy alone. It also delays the disease getting worse. The new results show that adding docetaxel to standard hormone therapy is cost-effective when used for men whose disease has spread to distant parts of their bodies. It is also very likely to be cost-effective for men with locally-advanced disease (which has grown outside the surface of the prostate but has not spread further). The health economics analysis also suggests that it may even reduce costs to the NHS when used to treat men with ...

Selective CRFs were updated for the activation of Protocol 17, these were:

• PR08 Form 1: Randomisation form
• PR08 Form 2: Baseline Assessment Forms
• PR08 Form 7: Follow Up Form
• PR08 Form 14: SAE reporting Form